FEATURED EDITORIAL
For drug discovery teams, the central question is whether metabolic signaling pathways can serve as a tractable new entry point into addiction therapeutics.
- GLP-1 Agonists In Addiction: Rationale And Drug Development
- Why Rare Cancers Are Often Left Behind In Drug Discovery
- Why Cell And Gene Therapies Break After Early Success
- AI: The Inflection Point In Retinal Drug Discovery, Development, And Delivery
- AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy
- Antibiotic-Resistant STIs: Men's Health Is Entering A New Era Of Therapeutic Risk
- If AI Can't Read Your Science, Investors Won't Either
FEATURED APPLICATION CONTENT
-
High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.
-
Accurate serial dilutions depend on more than calculations. Learn how mixing, tip handling, and workflow consistency influence accuracy, as well as how small adjustments can improve reproducibility.
-
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
- Next‑Generation Omics: Latest Insights From A Growing Field
- 5 Takeaways From The Boston Open Science & Innovation Forum
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- USF Scientists Examine AI's Real-World Readiness For Drug Discovery
- InnoCare Announces Approval Of Clinical Trial Of Novel CDH7 Targeted ADC ICP-B208 In China
- Waiv Enters Collaboration With Daiichi Sankyo To Deliver AI-Derived Biomarkers For ADC Program
- Researchers Identify Potential New Route For Antimalarial Drug Design
- Simulations Plus And NVIDIA Collaborate To Scale GPU-Accelerated, AI-Assisted Modeling Workflows
- ZYUS Life Sciences Expands U.S. Patent Portfolio With Second Pain Management Patent
- Alloy Therapeutics And Institute For Protein Innovation Announce Strategic Collaboration To Advance Next-Generation Antibody Discovery
- SGS Acquires Keystone Bioanalytical, Strengthening End-To-End Drug Development Lifecycle Testing Capabilities For North American Pharma And Biotech Industries
- Cellenkos Announces FDA Clearance Of Investigational New Drug (IND) Application For Phase 1b/ 2a Trial Of CK0802 In Steroid-Refractory Graft-versus-Host Disease (GVHD)
- HanchorBio And NYCU Launch AI-Enabled Drug Discovery Collaboration To Advance Next-Generation Biologics
ARCHIVED NEWSLETTER
- 05.02.26 -- Drug Discovery Online Best Of April
- 04.29.26 -- Master pipetting, PCR, and NGS for cell and gene workflows.
- 04.28.26 -- Structural Biology Wages War On HIV And The Pandemics Of Tomorrow
- 04.24.26 -- Why Open-Source AI Models Matter For Computational Drug Discovery
- 04.14.26 -- Next Generation Omics: Latest Insights From A Growing Field
